clinical trial · NCT07691489
A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer
Colorectal CancerAdenocarcinoma of the ColonAdenocarcinoma of the RectumFam-Trastuzumab Deruxtecan-Nxki
brief summary
The purpose of this study is find out whether the combination of trastuzumab deruxtecan (T-DXd) and cetuximab is an effective treatment for participants with metastatic and/or unresectable colorectal cancer that expresses low levels of HER2 and that has gotten worse after receiving standard treatment.
started
Aug 1, 2026
primary completion
Jun 1, 2029
completion
Jun 1, 2029
last updated
Jul 9, 2026
official title
A Phase 2 Trial of Trastuzumab Deruxtecan in Combination With Cetuximab in HER2-low Metastatic Colorectal Cancer That Has Progressed on Standard Therapies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol